Holen Sie sich die Stockscreener-App
35.06
0.14%
-0.10
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$35.16
Offen:
$34.58
24-Stunden-Volumen:
748.09K
Relative Volume:
0.35
Marktkapitalisierung:
$3.14B
Einnahmen:
$333.87M
Nettoeinkommen (Verlust:
$-169.00M
KGV:
-17.19
EPS:
-2.04
Netto-Cashflow:
$-157.30M
1W Leistung:
+17.94%
1M Leistung:
+42.49%
6M Leistung:
+66.00%
1J Leistung:
+99.83%
1-Tages-Spanne:
$34.35
$35.86
1-Wochen-Bereich:
$29.37
$35.86
52-Wochen-Spanne:
$12.91
$35.86
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
35.24 | 3.15B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.25 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.23 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.03 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
829.86 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.66 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Results: Travere Therapeutics, Inc. Exceeded Expectations And The Consensus Lifted Next Year's Outlook - Yahoo Finance
Real time scanner hits for Travere Therapeutics Inc. explainedWeekly Earnings Recap & AI Driven Stock Price Forecasts - newser.com
Does Travere Therapeutics Inc. show high probability of rebound2025 Market WrapUp & Safe Capital Allocation Plans - newser.com
Can Travere Therapeutics Inc. stock hit analyst price targetsJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Can Travere Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Update Report & Weekly Breakout Opportunity Watchlist - newser.com
Cantor Fitzgerald Issues Negative Estimate for TVTX Earnings - MarketBeat
Will Travere Therapeutics Inc. stock outperform international peersEarnings Growth Summary & Weekly Hot Stock Watchlists - newser.com
Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings - Insider Monkey
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook - MSN
Will Travere Therapeutics Inc. stock gain from strong economyQuarterly Earnings Summary & Fast Momentum Entry Tips - newser.com
What indicators show strength in Travere Therapeutics Inc.July 2025 Institutional & Long-Term Investment Growth Plans - newser.com
When is the best time to exit Travere Therapeutics Inc.CEO Change & Free High Return Stock Watch Alerts - newser.com
Travere Therapeutics Stock (TVTX) Opinions on Q3 Earnings Surge - Quiver Quantitative
How geopolitical tensions affect Travere Therapeutics Inc. stockJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - newser.com
Jennison Associates LLC Sells 80,602 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Pattern recognition hints at Travere Therapeutics Inc. upsideQuarterly Trade Summary & Weekly High Return Stock Opportunities - newser.com
10 Stocks With Easy 20-40% Gains - Insider Monkey
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2025 Earnings Call Transcript - Insider Monkey
TD Cowen Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Why Travere Therapeutics Inc. stock could outperform in 2025Market Trend Report & Reliable Price Breakout Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
A Look at Travere Therapeutics's Valuation Following Strong Q3 Profit and FILSPARI Momentum - Yahoo Finance
Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High Following Earnings Beat - MarketBeat
Travere Therapeutics (TVTX) Is Up 25.3% After FILSPARI Drives Q3 Profit Turnaround and Global Milestone - Yahoo Finance
Travere Therapeutics stock hits 52-week high at 33.66 USD By Investing.com - Investing.com Australia
Travere Therapeutics (TVTX): Unprofitable But Forecast 67% Annual Earnings Growth Challenges Bearish Narratives - Yahoo Finance
TD Cowen Raises Price Target for Travere Therapeutics (TVTX) to $40 | TVTX Stock News - GuruFocus
Travere Therapeutics’ Strong Quarter and Future Prospects - TipRanks
Travere Therapeutics Delivers Growth As FILSPARI Drives Profits - Finimize
Eric Dube Sells 92,872 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $79,860.00 in Stock - MarketBeat
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells 27,128 Shares of Stock - MarketBeat
Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M - MSN
Travere Therapeutics (NASDAQ:TVTX) Releases Quarterly Earnings Results, Beats Estimates By $0.59 EPS - MarketBeat
Travere Therapeutics stock hits 52-week high at 33.66 USD - Investing.com
Travere Therapeutics (TVTX) Sees Increased Price Target and Posi - GuruFocus
Top 2% Biotech Screams Up A Beat On Its Linchpin Drug - Investor's Business Daily
Emerald Mutual Fund Advisers Trust Has $16.89 Million Stock Holdings in Travere Therapeutics, Inc. $TVTX - MarketBeat
Backtesting results for Travere Therapeutics Inc. trading strategiesMarket Movement Recap & Safe Entry Momentum Tips - newser.com
Travere therapeutics CEO Dube sells $3.6m in TVTX stock By Investing.com - Investing.com Canada
Can Travere Therapeutics Inc. stock maintain growth trajectoryRisk Management & Weekly Setup with ROI Potential - newser.com
Travere Therapeutics (TVTX) Exceeds Q3 Revenue Expectations, Eyes Future Growth - GuruFocus
Travere Therapeutics Swings to Q3 Non-GAAP Profit, Revenue Rises - MarketScreener
Analyzing drawdowns of Travere Therapeutics Inc. with statistical toolsWeekly Stock Report & Low Risk High Win Rate Stock Picks - newser.com
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):